Lotemax SM®
Loteprednol 0.38% · ophthalmic gel
Steroid
Approved uses
Post-operative inflammation and pain following ocular surgery
1 drop into the conjunctival sac of the affected eye TID beginning the day after surgery, continuing through the first 2 post-operative weeks
TID dosing leaves 74% pain free and 30% with complete cell clearance by day 8.
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
- Mycobacterial infection of the eye.
- Fungal diseases of ocular structures.
0.38% submicron gel (loteprednol etabonate 3.8 mg/g), 5 g in a 10 mL bottle
Corticosteroid. Corticosteroids have been shown to inhibit the inflammatory response to a variety of inciting agents. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. Glucocorticoids are known to bind to and activate the glucocorticoid receptor, but the molecular mechanisms of receptor-dependent modulation of inflammation are not clearly established. Corticosteroids are thought to inhibit prostaglandin production through several independent mechanisms. In 18 healthy adult subjects given one drop three times daily by bilateral ocular administration for up to two weeks, mean plasma C max was 0.13 ng/mL on Day 1 and 0.16 ng/mL on Day 15, and the lower limit of quantitation was 0.05 ng/mL.
Warnings & Precautions
- IOP elevation and glaucoma: Prolonged corticosteroid use may result in glaucoma with optic nerve damage and defects in visual acuity and visual fields; use with caution in the presence of glaucoma, and monitor IOP if this product is used 10 days or longer.
- Posterior subcapsular cataract: Corticosteroid use may produce it.
- Delayed healing after cataract surgery: Steroids used after cataract surgery may delay healing and increase the incidence of bleb formation.
- Corneal or scleral perforation: In diseases causing thinning of the cornea or sclera, perforations have occurred with topical steroids.
- Prescription renewal: The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
- Secondary ocular infection: Prolonged use may suppress host response and increase the hazard of secondary ocular infection; in acute purulent conditions of the eye steroids may mask infection or enhance existing infection.
- Viral infection exacerbation: Ocular steroids may prolong the course and worsen the severity of many ocular viral infections including herpes simplex; a history of herpes simplex requires great caution.
- Fungal infections: Fungal corneal infection is particularly prone to develop coincidentally with long-term local steroid use; consider fungal invasion in any persistent corneal ulceration where a steroid has been used or is in use, and culture when appropriate.
- Contact lens wear: Lenses should not be worn when the eyes are inflamed.
Common Side Effects
Clinical trial reactions: No treatment-emergent adverse drug reaction occurred in more than 1% of subjects in the three times daily group compared with vehicle. Corticosteroid class effects: Adverse reactions associated with ophthalmic steroids include elevated IOP, which may be associated with infrequent optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing and secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.
Pregnancy: No adequate and well controlled studies in pregnant women. Oral dosing produced teratogenicity at clinically relevant doses, with malformations in rabbits at 4.2 times the recommended human ophthalmic dose (spina bifida including meningocele at 0.1 mg/kg, exencephaly and craniofacial malformations at 17 times) and in rats at 106 times. Abortion and resorption occurred in rabbits at 256 times, and offspring survival was reduced in rats at 10.6 times. The background risk for the indicated population is unknown; in the U.S. general population it is 2% to 4% for major birth defects and 15% to 20% for miscarriage of clinically recognized pregnancies.
Lactation: No data on the presence of drug in human milk, on effects in the breastfed infant, or on milk production; weigh the developmental and health benefits of breastfeeding against the clinical need and potential adverse effects.
Safety and effectiveness in pediatric patients have not been established.